Breast Implant Safety Statistics Report
core-study and meta-analysis figures on one page

Medically reviewed by Dr. Junghyun Nam · Director, Umnagumo Plastic Surgery. Literature selection and compilation reviewed by the directing surgeon.

Published 2026-07-21 · figures current as of 2026-07

How common is reoperation?

The U.S. FDA’s 2011 safety summary, based on authorization studies, states that 20–40% of augmentation patients underwent reoperation for some reason within 8–10 years^[21]. Reoperation here means all causes, not only complication treatment but also requests to change size or shape. In one 10-year authorization study the leading reason for reoperation was not a complication but the patient’s request to change size or style^[6].

Recently approved implants have shorter follow-up at authorization. Motiva’s FDA data (2024 SSED), for example, reported a 3-year reoperation rate of 6.1% (95% CI 4.3–8.8) in its primary-augmentation cohort, with longer-term results tracked and reported through post-approval studies (PAS)^[5]. Because follow-up and detection methods differ, such figures cannot be placed next to the 10-year cumulative value above and read as “which implant is better.”

Capsular contracture — how it accumulates over time

Capsular contracture (Baker III/IV), where the capsule around the implant thickens and contracts, accumulates steadily over long follow-up. Following the time axis within a single authorization study looks like this.

Absolute figures per product cannot be lined up or ranked, because each study’s design, population, and follow-up differ. What carries more interpretive value is a within-study subgroup comparison. Another FDA authorization study (Natrelle round) reported 10-year contracture split by the layer the implant was placed in (pocket plane), within its own cohort.

The same direction holds in a 2025 meta-analysis pooling 24 studies — the odds of contracture with submuscular placement were lower than with prepectoral (subglandular + subfascial) placement (OR 0.35, 95% CI 0.25–0.50)^[8]. Pocket plane, however, is not chosen on contracture odds alone; tissue thickness, shape, and feel are weighed together. On the risk-factor side, a hematoma-present group showed higher contracture odds (OR 14.60), but with a 1.78–118.90 confidence interval — a very wide small-sample estimate, so it is safer to take only the direction (“a significant association”) than the multiplier itself^[9]. The preventive effect of post-operative massage was judged insufficient in evidence in a literature review^[10].

Why rupture figures differ so much between articles

No figure is as widely misread as the rupture rate. The key point is that how it was detected determines the number. Even within the same MemoryGel authorization program, the value differed by analysis method^[2][3].

Since these two analyses differ in timepoint, detection method, and follow-up rate, reading them as “rupture rose 22-fold in six years” is wrong. What the two values say is one thing — silicone implant rupture is often silent, so the more actively you look for it with routine MRI, the larger the number. The same tendency appears elsewhere. In a Danish cohort, rupture risk was very low early on and rose significantly after 6–8 years^[11], and in a single-center study of implants in place for 3–20 years, 82 of 584 patients (14%) had suspected rupture on ultrasound, with asymptomatic prevalence estimated at about 10.6%^[12]. Symptoms and management of rupture are covered in the implant rupture guide.

The first month after surgery, in numbers

Early complications distort if merged into one table, because definitions and denominators differ by study. The four values below are independent values from different studies, each with its study-specific conditions stated alongside it.

Sensory change has figures too. In a prospective study of 162 subfascial-augmentation patients (objective monofilament measurement), the share of nipple-areola complexes (NAC) whose sensation had not recovered at 12 weeks was 4% of all NAC (an NAC-based, not per-patient, figure). The FDA notes that sensory change may be temporary or permanent^[16].

When, and with which imaging, is screening done?

The U.S. FDA’s 2020 recommendation is a screening interval, not a replacement interval — a first ultrasound or MRI at 5–6 years for silicone gel implants, then every 2–3 years, even when asymptomatic^[1]. The diagnostic accuracy of that imaging was reported as follows in a meta-analysis pooling 21 studies and 1,098 implants.

The asymptomatic-screening figures came out lower than the symptomatic ones, but this subgroup difference was not statistically significant in the original meta-analysis and the asymptomatic analysis included only 3 studies — a value to read for direction only. High-resolution ultrasound has a single-operator study reporting 90.9% sensitivity (95% CI 70.8–98.9) and 100% specificity on 104 surgically confirmed implants, but the sample is small and it can vary with operator skill^[18].

BIA-ALCL — the scale reported so far

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rarely reported condition that has been reported mainly in association with textured-surface implants. The FDA’s cumulative voluntary-report tally, compiled worldwide through 30 June 2024, is 1,380 reports, including 64 death reports^[19]. Two things matter in reading this. First, a cumulative voluntary-report tally is not an incidence rate — it is not a complete-registration system, so estimating true incidence requires separate epidemiological studies. Second, it does not mean every death report is a confirmed causal case. Individual implant studies sometimes cite “0 reports,” but 0 within a given study period does not mean 0% risk or a safety guarantee. The condition itself is covered in the BIA-ALCL guide.

How was the satisfaction measure reported?

Satisfaction was tracked in a large prospective study with the validated BREAST-Q patient-reported outcome score. In a silicone implant cohort the breast-satisfaction score moved as below — these are scores, not satisfaction rates. But the number of respondents falls at each timepoint: 11,295 at 1 year → 9,135 at 4 years (4-year response rate 58.2%), so this is not a full follow-up of the same participants and attrition bias is possible^[20].

Among respondents, the mean score was higher than the preoperative mean at the reported 1- and 4-year timepoints; this observational pattern does not establish an individual treatment effect. As shown above, reoperation was also accumulating over the same period — the two have to be read together for balance.

How this report selected its figures

• Only FDA authorization studies (including SSED originals), peer-reviewed journal papers, meta-analyses, and large registries were cited. Figures from secondary sources such as blogs or news were excluded.
• Every figure carries its sample size (n), follow-up, and detection method, because a probability without these three cannot be interpreted.
• Figures from different studies are never plotted in one chart. Every chart shows within-single-study values.
• The report is written on the principles that a voluntary-report tally is not an incidence rate, that an observational association is not causation, and that 0 within a study is not 0% risk.
• When new long-term follow-up is published, the body is updated and the last-updated date at the top is raised.

When citing figures from this report, please also credit the original paper or authorization document for each item as the primary source. All figures are observed values from published literature, not this clinic’s surgical outcomes, and individual results vary.

Full reference list

1. U.S. FDA, Breast Implants — imaging screening interval for asymptomatic silicone implants (first ultrasound/MRI at 5–6 years, then every 2–3 years)
2. Caplin et al., MemoryGel Core Study 10-year final report, Plast Reconstr Surg, 2021 (primary augmentation n=552; rupture from MRI cohort A n=202)
3. Cunningham, MemoryGel 6-year report, 2009
4. Spear & Murphy, Natrelle round 10-year Core Study, Plast Reconstr Surg, 2014
5. FDA PMA P230005 SSED, 2024 (Motiva authorization data; primary augmentation 3-year reoperation 6.1%)
6. Maxwell et al., Natrelle 410 10-year Core Study reoperation reasons, Aesthet Surg J, 2015
7. Reasons-for-explantation distribution — cosmetic primary-augmentation subgroup 463 patients/903 breasts (1994–2022), Aesthetic Plast Surg, 2023
8. Haas et al., pocket plane (submuscular vs prepectoral = subglandular + subfascial) and capsular contracture meta-analysis (24 studies), Aesthet Surg J Open Forum, 2025
9. Li & Xiao, capsular contracture risk-factor retrospective study (n=212), Front Surg, 2025
10. Sood et al., post-operative massage evidence review, Eplasty, 2017
11. Hölmich et al., time-dependence of rupture risk cohort, Arch Surg, 2003
12. Salzman, ultrasound rupture findings and asymptomatic prevalence estimate (584 patients), Plast Reconstr Surg, 2021
13. Hemmingsen et al., primary augmentation 1,128-patient cohort (hematoma/infection timing), JPRAS, 2022
14. Mesa et al., infection 5-year cohort (9,691 patients), PRS Glob Open, 2021
15. Valente et al., TOPS registry 30-day serious adverse events (84,296 patients), Plast Reconstr Surg, 2021
16. Brown, subfascial augmentation nipple-areola (NAC) sensation prospective study (162 patients), Aesthet Surg J, 2016
17. Song et al., MRI rupture diagnostic-accuracy meta-analysis (21 studies, 1,098 implants; subgroup difference not statistically significant), Plast Reconstr Surg, 2011
18. Glener et al., high-resolution ultrasound diagnostic accuracy, Aesthet Surg J, 2025
19. U.S. FDA, BIA-ALCL Medical Device Reports tally (as of 2024-06-30)
20. Alderman et al., BREAST-Q prospective observational study (silicone cohort; respondents decline over time, 4-year response rate 58.2%), Plast Reconstr Surg, 2016
21. U.S. FDA, Update on the Safety of Silicone Gel-Filled Breast Implants — 2011 Executive Summary (20–40% of augmentation patients reoperated within 8–10 years)

Frequently asked questions